CytomX Therapeutics, Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↑+19.2% +$5M
$-21M
Free Cash Flow↓-151.3% -$121K
$-201K
Investing Cash Flow↓-97.6% -$18M
$439K
Financing Cash Flow↑+640.0% +$14M
$17M
Capex↑+151.3% +$121K
$201K
Stock-Based Comp↓-21.5% -$405K
$1M
D&A↓-80.0% -$400K
$100K
SBC Allocated Expense↓-21.5% -$405K
$1M